Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 13, 2012, Pages 6162-6175

  Harikrishnan, Lalgudi S ^a   Finlay, Heather J ^a   Qiao, Jennifer X ^a   Kamau, Muthoni G ^a   Jiang, Ji ^a   Wang, Tammy C ^a   Li, James ^a   Cooper, Christopher B ^a   Poss, Michael A ^a   Adam, Leonard P ^a   Taylor, David S ^a   Chen, Alice Ye A ^a   Yin, Xiaohong ^a   Sleph, Paul G ^a   Yang, Richard Z ^a   Sitkoff, Doree F ^a   Galella, Michael A ^a   Nirschl, David S ^a   Van Kirk, Katy ^a   Miller, Arthur V ^a   Huang, Christine S ^a   Chang, Ming ^a   Chen, Xue Qing ^a   Salvati, Mark E ^a   Wexler, Ruth R ^a   Lawrence, R Michael ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLOROPYRIDIN 2 YL) 2 PHENYL 1 [3 (TRIFLUOROMETHYL)PHENYL]ETHYL 3,3 DIMETHYLBUTANOATE; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (1,1,2,2 TETRAFLUOROETHOXY)PHENYL] 2 PHENYLETHYL] 3 CYCLOPENTYLURE; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (1,1,2,2-TETRAFLUOROETHOXY)PHENYL] 2 PHENYLETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL) 2 (4 FLUOROPHENYL)ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 2 (1H 1,2,4 TRIAZOL 5 YL)ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 2 (4 METHYLTHIAZOL 2 YL)ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 2 (PYRIDIN 2 YL)ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 2 PHENYLETHYL] 3 CYCLOPENTYLUREA DERIVATIVE; 1 [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL]BUT 3 ENYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 2 PHENYL 1 [3 (1,1,2,2 TETRAFLUOROETHOXY)PHENYL]ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 2 PHENYL 1 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CHLOROPYRIDIN 2 YL) 2 PHENYL 1 [3 (TRIFLUOROMETHYL) PHENYL]ETHYL] 3 CYCLOPENTYLUREA; 1 [1 (5 CYANOPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 2 PHENYLETHYL] 3 CYCLOPENTYLUREA; 1 [1 (6 CHLOROPYRIDIN 3 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL) PHENYL] 2 PHENYLETHYL] 3 CYCLOPENTYLUREA; 1 CYCLOPENTYL 3 [1 (5 FLUOROPYRIDIN 2 YL) 2 PHENYL 1 [3 (TRIFLUOROMETHYL)PHENYL]ETHYL]UREA; 1 CYCLOPENTYL 3 [1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 1 (5-FLUOROPYRIDIN 2 YL) 2 PHENYLETHYL]UREA; 1 CYCLOPENTYL 3 [1 [3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL] 1 (6 METHOXYPYRIDIN 3 YL) 2 PHENYLETHYL]UREA; 1 CYCLOPENTYL 3 [2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL]ETHYL]UREA; 1 TERT BUTYL 3 (2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL]UREA; 2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (1,1,2,2 TETRAFLUOROETHOXY)PHENYL]ETHYL 3,3 DIMETHYLBUTANOATE; 3,3 DIMETHYL N [2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL]BUTANAMIDE; 4 FLUORO N [2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; 4 FLUORO N [2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL]BENZAMIDE; [1 (5 CHLOROPYRIDIN 2 YL) 1 [3 FLUORO 5 (TRIFLUOROMETHYL) PHENYL] 2 (5 METHYL 1,2,4 OXADIAZOL 3 YL)ETHYL] 3 CYCLOPENTYLUREA; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIPHENYLPYRIDYLETHANAMINE DERIVATIVE; ETHYLAMINE; N (2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL] 3 (TRIFLUOROMETHYL)BENZAMIDE; N (2 PHENYL 1 (PYRIDIN 2 YL) 1 [3 (TRIFLUOROMETHYL)PHENYL)ETHYL]BENZAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HAMSTER; MOUSE; NONHUMAN;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; BLOOD PRESSURE; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY DISEASE; CRICETINAE; DRUG DISCOVERY; HEART RATE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; PYRIDINES; RATS; STILBENES;

EID: 84863815186     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300611v     Document Type: Article

References (25)

1. Sacks, F. M. Lipid and lipoprotein metabolism, and risk for cardiovascular disease Metab. Risk Cardiovasc. Dis. 2011, 18-40
2. Goldenberg, N.; Glueck, C. Statins efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk Vasc. Health Risk Manage. 2009, 5, 369-376
3. Rhoads, G. G.; Gulbrandsen, C. L.; Kagan, A. Serum lipoproteins and coronary heart disease in a polulation study of Hawaii Japanese men N. Engl. J. Med. 1976, 294, 293-298
4. Castelli, W. P.; Garrison, R. J.; Wilson, P. W.; Abbott, R. D.; Kalousdian, S.; Kannel, W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA, J. Am. Med. Assoc. 1986, 256, 2835-2838 (Pubitemid 17178361)
5. Kannel, W. B. Range of serum cholesterol values in the population developing coronary artery disease Am. J. Cardiol. 1995, 76, 69c-77c
6. Virani, S. S.; Ballantyne, C. M. Therapy and clinical trials: HDL-cholesterol and niacin therapy: past, present, and future Curr. Opin. Lipidol. 2010, 21, 165-166
7. Barter, P. J.; Brewer, H. B.; Chapman, M. J.; Hennekens, C. H.; Rader, D. J.; Tall, A. R. Cholesteryl ester transfer protein Arterioscler., Thromb., Vasc. Biol. 2003, 23, 160-167
8. For a recent review see the following: Weber, O.; Bischoff, H.; Schmeck, C.; Bottcher, M. Cholesteryl ester transfer protein and its inhibition Cell. Mol. Life Sci. 2010, 67, 3139-3149
9. Chapman, M. J.; LeGoff, W.; Guerin, M.; Kontush, A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors Eur. Heart J. 2010, 31, 149-164
10. Linsel-Nitschke, P.; Tall, A. R. HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat. Rev. Drug Discovery 2005, 4, 193-205 and references therein. (Pubitemid 40372554)
11. Boettcher, M.-F.; Heinig, R.; Schmeck, C.; Kohlsdorfer, C.; Ludwig, M.; Schaefer, A.; Gelfert-Peukert, S.; Wensing, G.; Weber, O. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein Br. J. Clin. Pharmacol. 2012, 73, 210-218
12. Shinkai, H. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents Expert Opin. Ther. Pat. 2009, 19, 1229-1237
13. Ruggeri, R. B. Cholesteryl ester transfer protein: pharmacological inhibition for the modulation of plasma cholesterol levels and promising target for the prevention of atherosclerosis Curr. Top. Med. Chem. 2005, 5, 257-264 and references therein (Pubitemid 40614127)
14. Sikorski, J. A. Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease J. Med. Chem. 2006, 49, 1-22 (Pubitemid 43077315)
15. Krishna, R.; Anderson, M. S.; Bergman, A. J.; Jin, B.; Fallon, M.; Cote, J.; Rosko, K.; Chavez-Eng, C.; Lutz, R.; Bloomfield, D. M.; Gutierrez, M.; Doherty, J.; Bieberdorf, F.; Chodakewitz, J.; Gottesdiener, K. M.; Wagner, J. A. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies Lancet 2007, 370, 1907-1914 (Pubitemid 350192656)
16. Macromodel, version 7.2008; Schrodinger, LLC: New York, 2002
17. AMPAC, version 6.55; Semichem (P.O. Box 1649, Shawnee Mission, KS 66222), 1997
18. Based on the following: Bisgaier, C. L.; Minton, L. L.; Essenburg, A. D.; White, A.; Homan, R. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays J. Lipid Res. 1993, 34, 1625-1634. Vesicles containing BODIPY-cholesterol ester (Molecular Probes) as CE donor were incubated with CETP and LDL (as CE acceptor), and fluorescence was monitored. Hits were identified as compounds that inhibited fluorescence greater than ∼50%. (Pubitemid 23264335)
19. Corte, J.; Hangeland, J.; Quan, M.; Smallheer, J. M.; Fang, T. Preparation of Pyridine Carboxamides as Serine Protease Inhibitors. WO2005123680, 2005.
20. Biel, J. H.; Warawa, E. J. Substituted Pyridines. US 3413298, 1968. The first eluting enantiomer was the more potent antipode.
21. Satoh, T.; Taylor, P.; Bosron, W. F.; Sanghani, S. P.; Hosokawa, M.; La Du, B. N. Current progress on esterases: from molecular structure to function Drug Metab. Dispos. 2002, 30, 488-493 (Pubitemid 34456967)
22. Kamau, M. G.; Harikrishnan, L. S.; Finlay, H. J.; Qiao, J. X.; Jiang, J.; Salvati, M. E.; Poss, M. A.; Wexler, R. R.; Lawrence, R. M. Synthesis of tertiary carbinamines Tetrahedron. 2012, 68, 2696-2703
23. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J. P.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K. A.; Fisher, M. R.; Tall, A. R.; Brewer, B. Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 2007, 357, 2109-2122 (Pubitemid 350146106)
24. Stroes, E. S. G.; Kastelein, J. J. P.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin- aldosterone system in rats Br. J. Pharmacol. 2009, 158, 1763-1770
25. Clerc, R. G.; Stauffer, A.; Weibel, F.; Hainaut, E.; Perez, A.; Hoflack, J.; Benardeau, A.; Pflieger, P.; Garriz, J. M. R.; Funder, J. W.; Capponi, A. M.; Niesor, E. J. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels J. Hypertens. 2010, 28, 1676-1686